8 August 2025 in Digital Discovery
Protein–protein interactions are at the heart of biological processes. Understanding how proteins interact is key for deciphering their roles in health and disease, and for therapeutic interventions. However, identifying protein interaction sites, especially for intrinsically disordered proteins, is challenging. Here, we developed a deep learning framework to predict potential protein binding sites to 14-3-3 – a ‘central hub’ protein holding a key role in cellular signaling networks. After systematically testing multiple deep learning approaches to predict sequence binding to 14-3-3, we developed an ensemble model that achieved a 75% balanced accuracy on external sequences. Our approach was applied prospectively to identify putative binding sites across medically relevant proteins (ranging from highly structured to intrinsically disordered) for a total of approximately 300 sequences. The top eight predicted peptide sequences were experimentally validated in the wet-lab, and binding to 14-3-3 was confirmed for five out of eight sequences (Kd ranging from 1.6 ± 0.1 μM to 70 ± 5 μM). The relevance of our results was further confirmed by X-ray crystallography and molecular dynamics simulations. These sequences represent potential new binding sites within the 14-3-3 interactome (e.g., relating to Alzheimer's disease as the binding to tau is not the new part), and provide opportunities to investigate their functional relevance. Our results highlight the ability of deep learning to capture intricate patterns underlying protein–protein interactions, even for challenging cases like intrinsically disordered proteins. To further the understanding and targeting of 14-3-3/protein interactions, our model was provided as a freely accessible web resource at the following URL: https://14-3-3-bindsite.streamlit.app/.
10 October 2025 in ACS Sensors
Homogeneous immunoassays that allow direct in-sample detection of biomarkers provide an attractive alternative to traditional heterogeneous immunoassays that require multiple washing and incubation steps. We previously reported the development of RAPPID, a bioluminescent sensor platform that uses split luciferase complementation to enable sandwich immunoassays directly in solution. Although RAPPID provides many benefits over traditional heterogeneous immunoassays, it requires protein G-mediated photoconjugation of split luciferase fragments to the Fc part of IgG monoclonal antibodies. Here, we report a new generation of RAPPID sensors (RAPPID-M) that do not rely on photoconjugation of protein G, but instead use a generic antibody-binding domain derived from protein M. The use of protein M substantially expands the application of RAPPID to include protein G-incompatible but analytically important mouse IgG1 antibodies, as well as scFv and Fab antibody fragments. Moreover, binding of protein M is found to be essentially irreversible, abolishing the need for photo-cross-linking. RAPPID-M thus improves upon the original RAPPID platform by the mix-and-measure-type assembly of antibody-split-luciferase conjugates and its compatibility with a broader scope of antibody types without compromising and even improving the analytical performance.